PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2016 | 6 | 1 | A11-13
Article title

Tyrosine kinase inhibitors in hematologic malignancy: should we be concerned?

Authors
Content
Title variants
Languages of publication
EN
Abstracts
Keywords
Discipline
Publisher

Journal
Year
Volume
6
Issue
1
Pages
A11-13
Physical description
Contributors
  • University of Kansas Medical Center, Kansas City, Kansas, United States Correspondence, cbporter@kumc.edu
References
  • 1. Kantarjian HM, Giles FJ, Bhalla KN et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 2011; 117(4): 1141-1145.
  • 2. Saglio G, Kim DW, Issaragrisil S et al; ENESTnd Investigators. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362(24): 2251-2259.
  • 3. Kantarjian H, Shah NP, Hochhaus A et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362(24): 2260-2270.
  • 4. Valent P, Hadzijusufovic E, Schernthaner GH et al. Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood 2015; 125(6): 901-906.
  • 5. Quintás-Cardama A, Kantarjian H, O’brien S et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007; 25(25): 3908-3914.
  • 6. Montani D, Bergot E, Günther S et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012; 125(17): 2128-2137.
  • 7. Hoeper MM, Barst RJ, Bourge RC et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation 2013; 127(10): 1128-1138.
  • 8. Shah NP, Wallis N, Farber HW et al. Clinical features of pulmonary arterial hypertension in patients receiving dasatinib. Am J Hematol 2015; 90(11): 1060-1064.
  • 9. Szmit S. Is dasatinib-related pulmonary hypertension a clinical concern? Future Oncol 2015; 11(18): 2491-2494.
  • 10. Larson RA. Is there a best TKI for chronic phase CML? Blood 2015; 126(21): 2370-2375.
  • 11. Moslehi JJ, Deininger M. Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia. J Clin Oncol 2015; 33(35): 4210-4218.
  • 12. Kim TD, Rea D, Schwarz M et al. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia 2013; 27(6): 1316-1321.
Document Type
minireview
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-9fd32994-b845-4fe3-a9d6-4868720a9bd7
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.